Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03517137 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Study acronym: COBRA
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv10
  2. Results first posted: Aug 11, 2025v9
  3. Secondary endpoints: details revised at 3 of 3 entriesv8
  4. Primary endpoint revised
    • Secondary endpoints: 4 to 3
    v7
  5. Study sites: 19 to 16
    • Study completion date: Sep 1, 2023 to Nov 16, 2026
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Primary completion date: Mar 1, 2021 to Aug 28, 2023
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 22 to 19
    v4
  3. Site details revised at 5 of 22 sitesv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2018 to Aug 1, 2019
    • Study sites: 0 to 22
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced stage Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing regimens.
Trial Details
NCT Number NCT03517137
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Conditions
(from sponsor)		 Advanced Hodgkin Lymphoma
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov